Comparison of F(ab’)₂ versus Fab antivenom for pit viper envenomation: A prospective, blinded, multicenter, randomized clinical trial

References

• Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna A, et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 2008; 5:e218.
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 2012; 50:911–1164.
   PubMed Web of Science ®Google Scholar
• Langley RL, Morrow WE. Deaths resulting from animal attacks in the United States. Wilderness Environ Med 1997; 8:8–16.
   PubMed Web of Science ®Google Scholar
• Boyer L, Degan J, Ruha AM, Mallie J, Mangin E, Alagón A. Safety of intravenous equine F(ab’)2: insights following clinical trials involving 1534 recipients of scorpion antivenom. Toxicon 2013; 76:386–393.
   PubMed Web of Science ®Google Scholar
• Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37:181–195.
   PubMed Web of Science ®Google Scholar
• Norris RL, Bush SP, Smith J. Bites by venomous reptiles in Canada, the U.S. and Mexico. In: Auerbach PS, ed. Wilderness Medicine. 6th ed. Philadelphia: Saunders; 2012; 1011–1039.
   Google Scholar
• Gold BS, Dart RC, Barish RA. Bites of venomous snakes. NEJM 2002; 347:347–356.
   PubMed Web of Science ®Google Scholar
• Landon J, Smith DS. Merits of sheep antisera for antivenom manufacture. J Toxicol 2003; 22:15–22.
   Web of Science ®Google Scholar
• WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins. Available at: http://www.who.int/neglected_diseases/diseases/snakebites/en/ (Accessed June 19, 2014).
   Google Scholar
• Litovitz TL, Schmitz BF, Bailey KM. 1989 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1990; 8:394.
   PubMed Web of Science ®Google Scholar
• Litovitz TL, Holm KC, Bailey KM, Schmitz BF. 1991 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1992; 10:452.
   PubMed Web of Science ®Google Scholar
• CroFab®. Prescribing Information. Brentwood, TN 37027: Protherics Inc., 2012.
   Google Scholar
• Anavip®. Prescribing Information [pending FDA approval at the time of this writing]. Mexico D.F., Mexico: Instituto Bioclon S.A. de CV.
   Google Scholar
• Lavonas EJ, Schaeffer TH, Kokko J, Mlynarchek SL, Bogdan GM. Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: An integrative review. BMC Emergency Medicine 2009; 9:13.
   PubMedGoogle Scholar
• Boyer LV, Seifert SA, Clark RF, McNally JT, Williams SR, et al. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 1999; 159:706–710.
   PubMed Web of Science ®Google Scholar
• Boyer LV, Seifert SA, Cain JS. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom. Ann Emerg Med 2001; 37:196–201.
   PubMed Web of Science ®Google Scholar
• Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med 2001; 37:189–195.
   Google Scholar
• Boyer LV, Chase PB, Degan JA, Figge G, Buelna-Romero A, Luchetti C, Alagón A. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab’)2 antivenoms. Toxicon 2013; 74:101–108.
   PubMed Web of Science ®Google Scholar
• Ruha AM, Curry SC, Beuhler M, Katz K, Brooks DE, Graeme KA, et al. Initial post marketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann Emerg Med 2002; 39:609–615.
   PubMed Web of Science ®Google Scholar
• Bush SP, Seifert SA, Oakes J, Smith SD, Phan TH, Pearl SR, Reibling ET. Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American Rattlesnake bite patients. Toxicon 2013; 69:29–37.
   PubMed Web of Science ®Google Scholar
• Ruha AM, Curry SC, Albrecht C, Riley B, Pizon A. Late hematologic toxicity following treatment of rattlesnake envenomation with Crotalidae polyvalent immune Fab antivenom. Toxicon 2011; 57:53–59.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Ruha AM, Banner W, Bebarta V, Bernstein JN, Bush SP, et al.; Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011; 11:2.
   PubMedGoogle Scholar
• Bush SP, Seifert SA, Pearl SR. Continuous infusion of crotalidae polyvalent Fab (Ovine). In A Patient With Rattlesnake Envenomation. Presented at Biology of the Rattlesnakes, Tucson AZ, 2011. Published in Bush SP: Case study – rattlesnake envenomation. July 2012. In: Crotaline Snakebite Management: The role of CroFab Crotalidae Polyvalent Immune Fab (Ovine). BTG International, Inc. 2013.
   Google Scholar
• Ariaratnam CA, Sjostrom L, Raziek Z, Kularatne SA, Arachchi RW, Sheriff MH, et al. An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii). Trans Roy Soc Trop Med and Hyg 2001; 95:74–80.
   PubMed Web of Science ®Google Scholar
• Meyer WP, Habib AG, Onayade AA, Yakubu A, Smith DC, Nasidi A, et al. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: a randomized comparative trial with Institute Pasteur Serum (IPSER) Africa antivenom. Am J Trop Med Hyg 1997; 56:291–300.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Khatri V, Daugherty C, Bucher-Bartelson B, King T, Dart RC. Medically significant late bleeding after treated crotaline envenomation: a systematic review. Ann Emerg Med 2014; 63:71–78.e1.
   PubMed Web of Science ®Google Scholar
• Kitchens C, Eskin T. Fatality in a case of envenomation by Crotalus adamanteus initially successfully treated with polyvalent ovine antivenom followed by recurrence of defibrinogenation syndrome. J Med Toxicol 2008; 4:180–183.
   PubMedGoogle Scholar
• Amaral versus Loma Linda University. [CIV S801200] Superior Court of San Bernadino County, CA; 2011.
   Google Scholar
• Balow versus University of Cincinatti, 2009-Ohio-5448.
   Google Scholar
• Levine M, Ruha AM, Padilla-Jones A, Gerkin R, Thomas SH. Bleeding following rattlesnake envenomation in patients with pre-envenomation use of antiplatelet or anticoagulant medications. Acad Emerg Med 2014; 21:301–307.
   PubMed Web of Science ®Google Scholar
• Sanchez EE, Galan JA, Perez JC, Rodriguez-Acosta A, Chase PB, Perez JC. The efficacy of two antivenoms against the venom of North American snakes. Toxicon 2003; 41:357–365.
   PubMed Web of Science ®Google Scholar
• Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the assessment of Crotalid snakebite. Ann Emerg Med 1996; 27:321–326.
   PubMed Web of Science ®Google Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6:65–70.
   Web of Science ®Google Scholar
• de Roodt AR, Clement H, Dolab A, Litwin S, Hajos SE, Boyer L, Alagón A. Protein content of antivenoms and relationship with their immunochemical reactivity and neutralization assays. Clinical Toxicology 2014; 52:594–603.
   Web of Science ®Google Scholar
• French WJ, Hayes WK, Bush SP, Cardwell MD, Bader JO, Rael ED. Mojave toxin in venom of Crotalus helleri (Southern Pacific Rattlesnake): molecular and geographic characterization. Toxicon 2004; 44:781–791.
   PubMed Web of Science ®Google Scholar
• Dart RC, Seifert SA, Carroll L, Clark RF, Hall E, Boyer-Hassen LV, et al. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. Ann Emerg Med 1997; 30:33–39.
   PubMed Web of Science ®Google Scholar
• Miller AD, Young MC, DeMott MC, Ly BT, Clark RF. Recurrent coagulopathy and thrombocytopenia in children treated with crotalidae polyvalent immune fab: a case series. Pediatr Emerg Care 2010; 26:576–582.
   PubMed Web of Science ®Google Scholar